男人女人午夜视频免费,免费人妻无码不卡中文字幕系,国产A级三级三级三级,成年无码aⅴ片在线观看

表皮生長因子受體(EGFR)活性蛋白

Active Epidermal Growth Factor Receptor (EGFR)

ErbB-1; ErbB1; ER1; ERB-B1; MENA; HER1; Erythroblastic Leukemia Viral(v-Erb-B)oncogene Homolog,Avian; Proto-oncogene c-ErbB-1; Receptor tyrosine-protein kinase erbB-1

  • 表皮生長因子受體(EGFR)活性蛋白產(chǎn)品包裝(模擬)
  • 表皮生長因子受體(EGFR)活性蛋白產(chǎn)品包裝(模擬)
  • APA757Hu01.jpgFigure. SDS-PAGE
  • Certificate通過ISO 9001、ISO 13485質(zhì)量體系認證

活性實驗

The epidermal growth factor receptor (EGFR) is a growth factor receptor that induces cell differentiation and proliferation upon activation through the binding of one of its ligands. The receptor is located at the cell surface, where the binding of a ligand activates a tyrosine kinase in the intracellular region of the receptor. This tyrosine kinase phosphorylates a number of intracellular substrates that activates pathways leading to cell growth, DNA synthesis and the expression of oncogenes such as fos and jun. In addition, the interaction of Heparin Binding Epidermal Growth Factor Like Growth Factor (HBEGF) and EGFR can activate the EGFR signaling pathway, and then affect the biological behaviors of cell proliferation, differentiation and migration. Thus a functional binding ELISA assay was conducted to detect the interaction of recombinant human EGFR and recombinant human HBEGF. Briefly, EGFR was diluted serially in PBS with 0.01% BSA (pH 7.4). Duplicate samples of 100 μl were then transferred to HBEGF-coated microtiter wells and incubated for 1h at 37℃. Wells were washed with PBST and incubated for 1h with anti-EGFR pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody for 1h at 37℃, wells were aspirated and washed 5 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37℃. Finally, add 50 μL stop solution to the wells and read at 450/630 nm immediately. The binding activity of recombinant human EGFR and recombinant human HBEGF was shown in Figure 1, the EC50?for this effect is 0.16 ug/mL.

用法

Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

儲存

避免反復(fù)凍融。2-8°C不超過一個月,-80°C不超過12個月。

穩(wěn)定性

熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗決定,具體方法如下:在37°C孵育48小時,沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi),在適當?shù)臈l件下存儲,損失率低于5%。

相關(guān)產(chǎn)品

編號適用物種:Homo sapiens (Human,人)應(yīng)用(僅供研究使用,不用于臨床診斷!)
APA757Hu01表皮生長因子受體(EGFR)活性蛋白Cell?culture;?Activity?Assays.
APA757Hu02表皮生長因子受體(EGFR)活性蛋白Cell?culture;?Activity?Assays.
APA757Hu62表皮生長因子受體(EGFR)活性蛋白Cell?culture;?Activity?Assays.
RPA757Hu01表皮生長因子受體(EGFR)重組蛋白Positive Control; Immunogen; SDS-PAGE; WB.
APA757Hu61表皮生長因子受體(EGFR)活性蛋白Cell?culture;?Activity?Assays.
EPA757Hu62表皮生長因子受體(EGFR)真核蛋白Positive Control; Immunogen; SDS-PAGE; WB.
RPA757Hu02表皮生長因子受體(EGFR)重組蛋白Positive Control; Immunogen; SDS-PAGE; WB.
EPA757Hu61表皮生長因子受體(EGFR)真核蛋白Positive Control; Immunogen; SDS-PAGE; WB.
PAA757Hu06表皮生長因子受體(EGFR)多克隆抗體WB; IHC; ICC; IP.
PAA757Hu02表皮生長因子受體(EGFR)多克隆抗體WB; IHC; ICC/IF
PAA757Hu01表皮生長因子受體(EGFR)多克隆抗體WB; ICC/IF
FAA757Hu51抗表皮生長因子受體(EGFR)多克隆抗體(別藻藍蛋白標記)FCM
MAA757Hu27表皮生長因子受體(EGFR)單克隆抗體WB; IHC; ICC; IP.
MAA757Hu29表皮生長因子受體(EGFR)單克隆抗體WB; IHC; ICC; IP.
RAA757Hu21表皮生長因子受體(EGFR)重組抗體WB; IF; ICC; IHC; IP; FCM.
MAA757Hu21表皮生長因子受體(EGFR)單克隆抗體WB; IHC
MAA757Hu23表皮生長因子受體(EGFR)單克隆抗體WB; ICC/IF
MAA757Hu24表皮生長因子受體(EGFR)單克隆抗體WB; IHC; ICC/IF
MAA757Hu25表皮生長因子受體(EGFR)單克隆抗體WB; ICC/IF
MAA757Hu22表皮生長因子受體(EGFR)單克隆抗體WB; IHC
SEA757Hu表皮生長因子受體(EGFR)檢測試劑盒(酶聯(lián)免疫吸附試驗法)Enzyme-linked immunosorbent assay for Antigen Detection.
HEA757Hu表皮生長因子受體(EGFR)檢測試劑盒(酶聯(lián)免疫吸附試驗法,高敏型)Enzyme-linked immunosorbent assay for Antigen Detection.
AEA757Hu抗表皮生長因子受體抗體(Anti-EGFR)檢測試劑盒(酶聯(lián)免疫吸附試驗法)Enzyme-linked immunosorbent assay for Antibody Detection.
LMA757Hu表皮生長因子受體(EGFR)等多因子檢測試劑盒(流式熒光發(fā)光法)FLIA Kit for Antigen Detection.

參考文獻

雜志參考文獻
Thoracic CancerNimotuzumab combined with gemcitabine and cisplatin as second-line chemotherapy for advanced non-small-cell lung cancer[Wiley: source]
J Cent Nerv Syst Dis.?Increased Epidermal Growth Factor Receptor (EGFR) Associated with Hepatocyte Growth Factor (HGF) and Symptom Severity in Children with Autism …[Pubmed:25249767]
Mol Cancer TherGC1118, an anti-EGFR antibody with a distinct binding epitope and superior inhibitory activity against high-affinity EGFR ligands[PubMed: 26586721]
Cell Death Dis.?LINC01225 promotes occurrence and metastasis of hepatocellular carcinoma in an epidermal growth factor receptor-dependent pathway[Pubmed:26938303]
analytica chimica acta Microfluidic immunosensor based on mesoporous silica platform and CMK-3/poly-acrylamide-co-methacrylate of dihydrolipoic acid modified gold electrode for cancer biomarker detection.[pubmed:28335979]
TalantaEGFR detection in extracellular vesicles of breast cancer patients through immunosensor based on silica-chitosan nanoplatform[Doi: 10.1016/j.talanta.2018.10.016]
Bioorganic ChemistryDesign, synthesis, molecular docking and biological activity evaluation of some novel indole derivatives as potent anticancer active agents and apoptosis inducers[Pubmed: 30665034]
Journal of?enzyme?inhibition and medicinal chemistryNovel thienopyrimidine derivatives as dual EGFR and VEGFR-2 inhibitors: design, synthesis, anticancer activity and effect on cell cycle profile[Pubmed: 30919701]
Bioorganic ChemistryDesign and synthesis of new benzoxazole/benzothiazole-phthalimide hybrids as antitumor-apoptotic agents[]
Bioorganic ChemistrySynthesis and anticancer activity of bis-benzo [d][1, 3] dioxol-5-yl thiourea derivatives with molecular docking study[Pubmed: 31288134]
Oxidative Medicine and Cellular LongevityEvaluation of the Effect Derived from Silybin with Vitamin D and Vitamin E Administration on Clinical, Metabolic, Endothelial Dysfunction, Oxidative Stress Parameters?…[Pubmed: 31737175]
NeoplasiaPatient-derived xenograft (PDX) models of colorectal carcinoma (CRC) as a platform for chemosensitivity and biomarker analysis in personalized medicine[Pubmed: 33212364]
Association between Serum Epidermal Growth Factor Receptor and Cyclooxygenase-2 Levels in Patients with Non-small Cell Carcinoma of Lung[]
Synthesis, EGFR-TK inhibition and anticancer activity of new quinoxaline derivatives[]
IMMUNOLOGIC RESEARCHHumoral immune response to epidermal growth factor receptor in lung cancer[33495907]
European Journal of Medicinal ChemistryPyrazolo[3,4-d]pyrimidine-based dual EGFR T790M/HER2 inhibitors: Design, synthesis, structure¨Cactivity relationship and biological activity as potential antitumor and anticonvulsant agents[33545637]
Journal of Molecular StructureDesign, synthesis, antiproliferative evaluation, and molecular docking study of new quinoxaline derivatives as apoptotic inducers and EGFR inhibitors[]
ACS Appl Mater InterfacesEmitter–Quencher Pair of Single Atomic Co Sites and Monolayer Titanium Carbide MXenes for Luminol Chemiluminescent Reactions[34914377]
Bioorganic ChemistryDiscovery of new pyrimido [5, 4-c] quinolines as potential antiproliferative agents with multitarget actions: Rapid synthesis, docking, and ADME studies[Pubmed:35219045]